台州博之锐生物制药

Taizhou Bozhirui Biopharmaceutical is a specialized biological drug manufacturing subsidiary of Zhejiang Huahai Pharmaceutical. The company is primarily responsible for the industrialization and large-scale production of monoclonal antibodies and other recombinant protein therapeutics developed within the Huahai group. Its facilities in Taizhou are designed to meet international GMP standards, supporting both clinical-stage production and commercial supply. Bozhirui plays a pivotal role in Huahai's strategy to expand from small molecule generics into the high-growth biologics and biosimilars market. The company's production capabilities support a pipeline focused on oncology, ophthalmology, and inflammatory diseases. Currently, the site handles the production of approved biosimilars and several innovative biologics in mid-to-late stage clinical development.